On 20 November 2001, orphan designation (EU/3/01/067) was granted by the European Commission to Pharmion Ltd, United Kingdom, for thalidomide for the treatment of multiple myeloma.
The sponsorship was transferred to Celgene Europe Limited, United Kingdom, in November 2008.
Thalidomide has been authorised in the EU as Thalidomide Celgene since 16 April 2008.
- What is multiple myeloma?
Multiple myeloma is a cancer of a type of white blood cell called a plasma cell. Plasma cells are found in the bone marrow. The bone marrow is the spongy tissue inside the large bones in the body. Normally, the bone marrow makes cells called “blasts” that mature into several different types of blood cells that have specific functions in the body. These include red cells, white cells and platelets. Red blood cells carry oxygen and other materials to all tissues of the body. Platelets make the blood clot, and white blood cells fight infection. In multiple myeloma an excessive number of plasma cells are produced. Normally, the division of cells takes place in a controlled manner but with multiple myeloma, the process gets out of control and abnormal plasma cells multiply, producing many myeloma cells. These fill up the bone marrow and interfere with production of the normal white cells, red cells and platelets. This leads to a number of possible complications, which include anaemia, bone pain and fractures, raised levels of calcium in the blood and kidney disease. Multiple myeloma is life-threatening.
- What is the estimated number of patients affected by the condition*?
At the time of designation, multiple myeloma affected approximately 1.2 in 10,000 people in the European Union (EU)*. This is equivalent to a total of around 45,000 people, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: The number of patients affected by the condition is estimated and assessed for the purpose of the designation, for a European Community population of 377,000,000 (Eurostat 2001) and may differ from the true number of patients affected by the condition. This estimate is based on available information and calculations presented by the sponsor at the time of the application.
- What treatments are available?
The main treatment of multiple myeloma is chemotherapy (using drugs to kill cancer cells) usually combined with steroids (a group of chemical substances, belonging to a larger class of molecules, the so-called hormones, which have an effect on the activity of certain organs). Several products were authorised for the condition in the Community at the time of submission of the application for orphan drug designation. Radiotherapy (using high-dose x-rays or other high-energy rays to kill cancer cells) can be very useful to treat painful areas and weakened bones. Interferon alpha is a protein normally produced by the body during viral infections, such as flu. Sometimes a combination of interferon and chemotherapy may be used. Thalidomide could be of potential significant benefit for the treatment of multiple myeloma. The main reason is that it may offer a new way of killing cancer cells and stopping tumour growth in these patients. This assumption will have to be confirmed at the time of marketing authorisation. This will be necessary to maintain the orphan status.
- How is this medicine expected to work?
Cancers need to produce a network of new blood vessels in order to grow. Without forming these blood vessels cancers cannot grow. The theory is that thalidomide will prevent the myeloma from growing by preventing the development of new blood vessels and possibly also reducing the supply of oxygen and nutrients to the cancer cells.
- What is the stage of development of this medicine?
The evaluation of the effects of thalidomide in experimental models is ongoing.
At the time of submission of the application for orphan designation, no clinical trials in patients withmultiple myeloma were initiated.
Thalidomide was not marketed anywhere worldwide for multiple myeloma, at the time of submission. Orphan designation of thalidomide was granted in the United States for the treatment of multiple myeloma.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 7 September 2001 recommending the granting of this designation.
Update: Thalidomide (Thalidomide Celgene) has been authorised in the EU since 16 April 2008 for the treatment of myeloma.
- Opinions on orphan medicinal product designations are based on the following three criteria
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation
|Name||Language||First published||Last updated|
|EU/3/01/067: Public summary of positive opinion for orphan designation of thalidomide for the treatment of multiple myeloma||(English only)||2008-07-29||2011-06-30|
|Medicine Name||Thalidomide Celgene|
|Disease/condition||Treatment of multiple myeloma|
|Date of decision||20/11/2001|
|Orphan decision number||EU/3/01/067|
Review of designation
Sponsor’s contact details:
Celgene Europe Limited
1 Longwalk Road
Middlesex UB11 1DB
Telephone: +44 208 831 83 00
Telefax: +44 208 831 83 01
For contact details of patients’ organisations whose activities are targeted at rare diseases see:
- Orphanet, a database containing information on rare diseases which includes a directory of patients’ organisations registered in Europe.
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.